Clinical Trial

A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma

Name: A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma — clinical trial record (NCT07760454)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a Phase I/II, single-arm, open-label, multicenter clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM). The study aims to evaluate the safety, tolerability, efficacy, cellular kinetics, and immunogenicity of CT0596.

Trial Details

NCT Number	NCT07760454
Lead Sponsor	UCARsgen Biotech Limited
Conditions	Relapsed/Refractory Multiple Myeloma
Enrollment	68 participants
Start Date	2026-09-01
Primary Completion	2030-12-31 (estimated)
Study Completion	2031-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-12